% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • most likely headed to 100 or lower, awful market, fear rules.

  • Reply to

    More LGND softness...

    by soflaturtle Jun 18, 2016 11:13 AM

    Since this post, LGND is down (but not as much as I expected...), and BIS is way up.

    Brexit was one of my many fears. Now that Brexit is a reality, many (ie, almost everyone) are saying that mkts could be down for the next few months. If you have a Schwab account, you got some news about this just yesterday or today. They say months of lower prices. I don't get it, but I am repeating what everyone seems to be saying.

    My bad, I got out of BIS and my QID on Wed when all the talking heads said the Brexit would fail. (those are the same talking heads that say mkts could be down for months, so consider that too)

    I still like LGND, but I am fearful that mkts could have a very tuff next few months, and would not be surprised to see them all lower, and LGND a lot lower.

    NP in LGND, and as of yesterday, a very minimal exposure to biotech/drug plays. I won't try again until at least mid-summer. If you are still holding, consider the BIS hedge, or put in protective stops, or buy some puts, and GL.

  • The UK was UK was against it. Brits are dips.

  • Irish a Scottish Tax inversion Biotechs voted against the Brexit and by trying to separating from the UK could yield enormous gains in good companies in these companies.

  • June 22, 2016
    Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV Ganaxolone IV Program Aimed at Status Epilepticus Target Indication
    RADNOR, Pa., June 22, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical
    company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today
    announced that it has dosed the first subject in its Phase 1 clinical trial of ganaxolone IV, an intravenous (IV) formulation of
    Marinus' CNS-selective GABA modulator, for the treatment of status epilepticus (SE). The study is designed to evaluate the A
    safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers, with data anticipated in the second half of 2016.
    Albena Patroneva, M.D., chief medical officer of Marinus Pharmaceuticals, commented, "Status epilepticus is a life- threatening medical emergency associated with high mortality and limited treatments. Typically, single or combination IV antiepileptic drugs are used in an attempt to break the seizures, however there are approximately 45,000 patients in the U.S. who do not respond to treatment and progress to established SE. Our preclinical research suggests ganaxolone IV could be a promising therapeutic in this difficult to treat seizure disorder, especially after first-line benzodiazepine treatment fails to halt the seizures. We look forward to reporting the results on this Phase 1 study later this year."
    Christopher M. Cashman, chief executive officer of Marinus Pharmaceuticals, added, "Dosing the first subject with ganaxolone IV in SE is an important event for Marinus as we focus the development of ganaxolone on target patient populations where we believe there to be a strong mechanistic rationale for a therapeutic benefit with ganaxolone. Strategically, we believe that ganaxolone IV in combination with our convenient oral capsule and liquid formulations, has the potential to

    Sentiment: Strong Buy

  • While I am careful about referring anyone to SA, I usually keep my largest holdings in a list at SA, and they notify you when there's an article about that company.

    The authors are individuals who get paid by the number of reads of their articles. Some are good, some are pure spam.

    If you sign up for NFLX or GILD, you will get emails every day. People post articles about those stocks bcse a lot of people own them, and read everything. I would suggest that 99% of the GILD articles have been wrong/trash.

    LGND is rarely written about, it's a smaller audience, so no one is writing about them

    Remember, on SA, no one is writing to put out good info, they are all writing to get views, which is how they get paid.

    But I do it anyway...

  • Reply to

    Why is P/E of this stock so low (9.xx)

    by djhmk4 Jun 22, 2016 10:30 AM

    They had a large tax benefit in FY 2015. That won't be repeated. According to the Q1FY2016 earnings press release, they project $3.41 to $3.46 per share in earnings for FY 2016, or about a 34 P/E. They project $5.03 in earnings per share for FY 2017, or about a 23 P/E.

  • Many tutes are adding . P/E is 9.46 unlike what other posters claim.

  • 1832 Asset Management L.P. purchased a new stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) during the first quarter, Holdings Channel reports. The firm purchased 469,700 shares of the biotechnology company’s stock, valued at approximately $80,340,000. 1832 Asset Management L.P. owned 2.36% of Ligand Pharmaceuticals at the end of the most

  • Thanks again for your help! :-)

  • Thks for posting, long! Thislooks like good news to me ...this company has lots of potential imo

  • June 16, 2016
    Oncobiologics Announces First CTA Approvals For Global Phase 3 Clinical Program For ONS-3010 (Humira® Biosimilar)
    Clinical Program Designed to Enable Interchangeability with Humira in U.S.
    CRANBURY, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Phase 3 clinical plan for ONS-3010 (Humira® biosimilar) has received the first of its European Union (EU) clinical trial authorization (CTA) approvals, including in the United Kingdom, Germany and Spain, for the biosimilarity study portion of the Phase 3 clinical program.
    The global Phase 3 clinical program for ONS-3010 is expected to include recruitment and treatment of patients in approximately 20 countries, including the United States and various member states of the EU. The program study design is based on input from multiple Health Authorities including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and will include testing intended to enable interchangeability for Humira® in the United States. The Phase 3 program will be conducted in patients with moderate to severe plaque psoriasis and is anticipated to begin dosing patients later in 2016.
    “We are excited to move to this final clinical confirmatory stage to demonstrate that ONS-3010 is biosimilar to Humira,” said Kenneth Bahrt, M.D., Chief Medical Officer of Oncobiologics. “This study marks the beginning of our first Phase 3 program and is supported by positive data from our previous Phase 1 study of ONS-3010.”
    Oncobiologics Chairman and Chief Executive Officer Pankaj Mohan, Ph.D., added, “These CTA approvals are another important step for Oncobiologics as we move to this final clinical confirmatory stage to demonstrate that ONS-3010 is biosimil

    Sentiment: Strong Buy

  • I think you can find that info on the LGND website. I am willing to share any info and to discuss. Good luck with ypur DD.

  • Hi again,..Was just looking for discussion in general. I only invested a small amount - I just started investing last month, so this is all new to me (it was in a drug that will hopefully mean down the road my nephew with muscular dystrophy will live longer). It paid off, but now I am lookign for a few stocks to invest in for the long run - it does look like LIGAND is doing lots and yes - I agree with being patient - prob just because I am new I am anxious for some discussion that I want more discussion I will check the board periodically, and my stock of course. I may sign up for LIGAND e-mails, too - do you have a good source that e-mails you the latest, and if so, are you willing to share that info with me, please.

    Thanks so much for your responses!

  • I guess it is a quiet board. The best investor here is one who is patient. There are over a hundred programs here with over 85 partners where LGND stands to earn royalties and/or other revenue. Some are years away from fruition, some are small. But we have had some excellent developments this year and within the next 12 months there will be some major things happening. What are you looking to discuss?

  • Sorry - it was sofaturtle who posted but sais his message went elsewhere - so it was this board - but only you and sofa posted since my post....take care!

  • Thank you for responding, fud. I hope I am seeing all the messages - on another board someone said they posted something but it didn't show up ... anyway, at the time of writing this, you are the only person to write something since June 17. So hopefully I am seeing all messages posted since the 17.

    Good Luck in your investments!

  • I had tried to post a msg on this subject, and see it went into the yhoo was more exhaustive ands detailed than this summary.

    Basically, I was trying to say that BBH, the ETF indicator that I watch, had dropped to the point that it gave up 60% of the gain since the Feb lows.

    If LGND gave up 60% of it's gains, it would be at 103.

    With the Brexit issues, and the US economy being shaky, I have to think there's no rebound at least until the Brexit vote, and I have no idea what that vote will be, or how the mkt will react.

    I am out for now, and suggest if you are still long, maybe consider a BIS hedge position.

  • I am not aware of a more lively forum for discussions of LGND. You can visit the company website and under presentations there are archived webcasts and slidedecks. Also you can open a topic you wish to inquire about or comment on and see if folks want to discuss it. The stock price varies here but the underlying business is in a solid growth mode, imo.

Must Watch
111.79-3.32(-2.88%)Jun 24 4:00 PMEDT